American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6360)
  2. Solid Tumor Oncology Division (5501)
  3. Survivorship Research (1982)
  4. Genitourinary Oncology Service (1761)
  5. Surgery (1632)
  6. Epidemiology and Biostatistics (1476)
  7. GSK Faculty (1380)
  8. Population Sciences Research Program (1360)
  9. Gastrointestinal Oncology Service (1350)
  10. Hematologic Malignancies, Division of (1273)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2561)
  3. Editorial (73)
  4. Review (65)
  5. Guidelines (54)
  6. Correspondence (48)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6360)
  2. Solid Tumor Oncology Division (5501)
  3. Survivorship Research (1982)
  4. Genitourinary Oncology Service (1761)
  5. Surgery (1632)
  6. Epidemiology and Biostatistics (1476)

More Groups

People
  1. Robert Motzer (450)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (250)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8678)
  2. JCO Precision Oncology (166)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (4)

More Publications

Results (9142)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PRO-ACTIVE: Results of a pragmatic phase IV randomized trial comparing the effectiveness of prophylactic swallow intervention for patients receiving radiotherapy for head and neck cancer
    Meeting Abstract

    Hutcheson, K. A.; Fuller, C. D.; Pytynia, K. B.; Hope, A. J.; Ringash, J.; Thorpe, K.; Palma, D. A.; Theurer, J.; Mills, G.; Cracchiolo, J. R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816
    Meeting Abstract

    Forde, P. M.; Spicer, J.; Provencio, M.; Mitsudomi, T.; Awad, M. M.; Wang, C.; Lu, S.; Felip, E.; Broderick, S.; Swanson, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL): Update with 24 months of liso-cel follow-up (FU)
    Meeting Abstract

    Boardman, A. P.; Reguera, J. L.; Wang, P.; Ellis, J.; Bar, M.; Kumar, J.; Farazi, T. A.; Garcia-Sancho, A. M.; Izutsu, K.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Impact of MTAP deletion on immunotherapy outcomes in patients with mesothelioma
    Meeting Abstract

    Ross, J.; Ortiz, E.; Barraza, G.; Mayoral, M.; Ginsberg, M. S.; Luongo, A.; Arfe, A.; Zauderer, M. G.; Adusumilli, P. S.; Eckert, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • MRI radiomics to predict outcome of neoadjuvant chemotherapy in patients with muscle invasive bladder cancer undergoing radical cystectomy
    Meeting Abstract

    Schwartz, L. H.; Akin, O.; Gold, S.; Deng, Y.; Lema-Dopico, A.; Chahwan, S.; Nincevic, J.; Ruby, L.; Capanu, M.; Apte, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results
    Meeting Abstract

    Mar, N.; Petrylak, D. P.; Hoimes, C. J.; Rosenberg, J. E.; Flaig, T. W.; Gourdin, T. S.; Barata, P. C.; Henry, E.; Bilen, M. S.; George, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Arbuiso, A.; Gupta, A.; Bent, E. H.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Bedke, J.; Powles, T.; Valderrama, B. P.; Gupta, S.; Kikuchi, E.; Loriot, Y.; Galsky, M D.; Sridhar, S. S.; Yu, E. Y.; Hoffman-Censits, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • KEAP1 mutated renal cell carcinoma (RCC): Characterization of an emerging molecularly defined RCC subtype
    Meeting Abstract

    Carlo, M.; Chen, Y. B.; Knezevic, A.; Zong, G.; Bakouny, Z.; Kemel, Y.; Latham, A.; Liu, Y. L.; Shah, N. J.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save